Factors associated with recurrence in patients with curatively resected stage I–II lung cancer

Koo, Hyeon‐Kyoung; Jin, Sang-Man; Lee, Chang‐Hoon; Lim, Heon Kil; Yim, Jae Joon; Kim, Young Tae; Yang, Seung Wook; Yoo, Chul‐Gyu; Han, Sung Koo; Kim, Joo Hyun; Shim, Young‐Soo; Kim, Young Whan

doi:10.1016/j.lungcan.2010.11.013

Cited by 42 publications

(31 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…SUVmax ≥10 was the best independent predictor of disease-free survival and overall survival. Koo et al [14] investigated factors associated with recurrence in 310 patients with stage I or II disease. There were 106 recurrences in the study population and a SUVmax ≥4.5 was found to be an independent predictor of recurrence after resection, with an OR of 5.45.…”

Section: Discussionmentioning

confidence: 99%

Risk factors of postoperative recurrences in patients with clinical stage I NSCLC

et al. 2014

View full text Add to dashboard Cite

BackgroundDespite advances in radiation therapy, chemotherapy, and newly developed molecular targeting therapies, long-term survival after resection for patients with NSCLC remains less than 50%. We investigated factors predicting postoperative locoregional recurrences and distant metastases in patients with clinical stage I non-small-cell lung cancer (NSCLC) after surgical resection.MethodsAll patients with clinical stage I NSCLC, who underwent surgical resection between January 2002 and June 2006, were reviewed retrospectively. Multiple logistic regression analyses were used to identify independent risk factors for patients with locoregional recurrences and distant metastases.ResultsA total of 261 patients were eligible. Overall survival was significant related to locoregional recurrences (P = 0.03) and distant metastases (P <0.001). There were significant differences of locoregional recurrence in tumor differentiation (P = 0.032) and advanced pathological stage (P = 0.002). In the group of distant metastases, there were significant differences in tumor differentiation (P = 0.035), lymphovascular space invasion (P = 0.031). Among the relationship between pattern of distant metastasis and clinicopathologic variables in patients with clinical stage I NSCLC, SUVmax (P = 0.02) and tumor size (P = 0.001) had significant differences. According to multiple logistic regression analysis, tumor differentiation is the only risk factor of postoperative outcome for locoregional recurrence and serum CEA (>3.5 ng/mL) is the predictor of distant metastasis.ConclusionsTumor differentiation and serum CEA were predictors of postoperative relapse for clinical stage I NSCLC after surgical resection. Risk factors of postoperative recurrence in patients with clinical stage I NSCLC may enable us to optimize the patient selection for postoperative adjuvant therapies or neoadjuvant treatment before surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors of postoperative recurrences in patients with clinical stage I NSCLC

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[5,45,54,65] A more nuanced approach to surveillance for lung cancer may be needed. If we could predict which patients are more likely to experience recurrence of disease or development of a second primary lung cancer, [2,66] we might offer more aggressive surveillance to those individuals. Future work should explore risk stratification schemata based on patient, tumor, and other clinical factors that could guide tailored surveillance strategies.…”

Section: Discussionmentioning

confidence: 99%

“…[1] Early stage NSCLC is generally treated with curative intent therapy, but 5-year recurrence rates are estimated in the range of 9%-46%, even with treatment. [2][3][4][5][6][7] Routine surveillance of these patients is recommended to enable early detection of recurrences or new cancers. [8][9][10][11] Lung cancer surveillance has been recommended using two imaging modalities: chest radiography (CXR) and computed tomography (CT) scanning.…”

Section: Introductionmentioning

confidence: 99%

Surveillance Practice Patterns After Curative Intent Therapy for Stage I Non-small Cell Lung Cancer in the Medicare Population

Erb

Soulos²,

Tanoue³

et al. 2014

Chest

View full text Add to dashboard Cite

“…Оценка законо-мерности рецидива после операции и возможной токсич-ности, связанных с ПОРТ, определяет соотношение поль-за / риск в послеоперационной терапии.Даже если риск местных рецидивов при начальных стадиях рака легких, как правило, считается малым по сравнению с риском от-даленного рецидива, частота локального рецидива, край-не непостоянна, и по литературным данным, составляет от 6% до 45% при I стадии и от 7% до 55% для II стадии заболевания [32][33][34] Согласно всех приведенных выше исследований, ве-роятность развития рецидива заболевания определялась критериями T и N. Данную оценку можно охарактеризо-вать «количественной». Однако, на сегодняшний день, есть результаты работ, которые отражают значимость дру-гих -«качественных» факторов риска для местного и реги-онального рецидива.…”

Section: Wwwmalignanttumorsorg Journal Of Malignant Tumoursunclassified

Postoperative Radiotherapy of Non-Small Cell Lung Cancer

Муфазалов¹,

Шарипова²

2015

Zlokač. opuholi

View full text Add to dashboard Cite

Factors associated with recurrence in patients with curatively resected stage I–II lung cancer

Cited by 42 publications

References 29 publications

Risk factors of postoperative recurrences in patients with clinical stage I NSCLC

Risk factors of postoperative recurrences in patients with clinical stage I NSCLC

Surveillance Practice Patterns After Curative Intent Therapy for Stage I Non-small Cell Lung Cancer in the Medicare Population

Postoperative Radiotherapy of Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About